Lyubimova N V, Toms M G, Fu R G, Bondarenko Yu V
Klin Lab Diagn. 2013 Oct(10):71-2, 40-2.
The paper presents the results of neurospecific proteins S-100 and glial fibrillary acidic protein (GFAP) determination in blood serum samples of 145 neuro-oncology patients and 69 healthy people. The significant elevation of S-100 and GFAP was revealed in glioblastoma (G IV) patients compare to the patients with anaplastic astrocytoma (G III), benign meningioma (GI), celebral metastasis and healthy controls. The concentration of S-100 in blood serum of patients with anaplastic astrocytoma, benign meningioma, and celebral metastasis did not significantly differ among themselves, and in relation to the control group there was a significantly increase only in patients with cerebral metastasis. GFAP was characterized by high frequency of its detection in patients with glioblastoma (83%) compare to other groups of patients and healthy donors, in which it was practically undetectable. These data suggest the possibility of using GFAP as a marker of glioblastoma and S-100- as an additional biochemical criteria of cerebral lesions in oncology patients.
本文介绍了对145例神经肿瘤患者和69名健康人的血清样本中神经特异性蛋白S-100和胶质纤维酸性蛋白（GFAP）的检测结果。与间变性星形细胞瘤（G III级）、良性脑膜瘤（G I级）、脑转移瘤患者及健康对照相比，胶质母细胞瘤（G IV级）患者的S-100和GFAP显著升高。间变性星形细胞瘤、良性脑膜瘤和脑转移瘤患者血清中S-100的浓度彼此之间无显著差异，与对照组相比，仅脑转移瘤患者有显著升高。与其他患者组和健康供体相比，GFAP在胶质母细胞瘤患者中的检测频率较高（83%），而在其他组中几乎检测不到。这些数据表明，GFAP有可能作为胶质母细胞瘤的标志物，而S-100可作为肿瘤患者脑部病变的额外生化指标。
